查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1631129

胃食道逆流症治疗市场规模、份额、趋势分析报告：按药物类型、地区和细分市场预测，2025-2030 年

Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Type, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

胃食道逆流症治疗市场的成长与趋势

根据 Grand View Research, Inc. 的一份新报告，全球胃食道逆流症 (GERD) 治疗市场规模预计到 2030 年将达到 57.7 亿美元。

预计 2025 年至 2030 年间市场复合年增长率为 2.0%。这种增长是由于胃食道逆流症和其他胃肠道疾病的盛行率不断增加。此外，生活方式和饮食习惯的改变、GERD 管理设备的成功率低以及自我治疗需求的增加进一步推动了该行业的发展。

胃食道逆流和其他胃病的盛行率不断上升，推动着市场的成长。例如，据估计，总人口中约有13.98%患有GERD，这意味着全球整体约有10.3亿人患有GERD。发病率的增加推动了对适当治疗的需求。使用非处方药治疗不明疾病的人可能面临更高的风险。未经治疗的 GERD 不仅会增加不适感，还会导致进一步的医疗问题。

GERD 的治疗通常包括改变生活方式、手术治疗和药物治疗。对生活方式的改变没有反应的患者可以接受治疗性介入。治疗方法包括抗酸药、抗分泌药物（如 PPI 和组织胺 (H2) 受体拮抗剂 (H2RA)）以及促动力药物。法莫替丁和西咪替丁是经美国食品药物管理局（FDA）批准的两种 H2RA 药物，目前可在美国柜檯购买。另一种常用的 H2RA 药物雷尼替丁因在活性成分中发现意外杂质而存在潜在的健康风险和安全问题，已被撤回。

此外，主要企业正致力于胃食道逆流症的治疗。例如，2022 年 5 月，Phathom Pharmaceuticals 宣布 FDA核准Vonoprazan。 Vonoprazan 是一种用于治疗成人各级糜烂性食道炎的药物，旨在治癒和缓解胃灼热。此外，2022 年 11 月，JB Pharma 推出了 Runraft，这是一种可快速缓解胃酸倒流和胃灼热的新型配方。

胃食道逆流症治疗市场报告重点

  • 制酸剂药物将在 2024 年主导胃食道逆流治疗市场，因为制酸剂可以抵消胃中的酸，从而快速、短期缓解症状。
  • 由于不必要的情况而未经治疗，从而引发进一步的医疗问题，这推动了对适当治疗的需求。
  • 新兴市场的关键参与企业正致力于开发可帮助缓解胃食道逆流症 (GERD) 所引起的不适的药物。
  • 北美占据了最大的市场占有率，这得益于诊断技术的不断进步，促进了残疾患者的康復。

目录

第一章调查方法与范围

第 2 章执行摘要

3. GERD 治疗市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析 – 波特五力分析
    • PESTLE分析

4. GERD 治疗市场：按药物类型分類的业务分析

  • 2024 年和 2030 年各药物类型的市场占有率
  • 药物类型细分仪表板
  • 2018 年至 2030 年按药物类型分類的市场规模、预测与趋势分析
  • 制酸剂
  • H2受体阻断剂
  • 质子帮浦抑制剂 (PPI)
  • 促动力剂

第 5 章 胃食道逆流症治疗市场：按地区分類的估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 市场规模、预测趋势分析，2018-2030
  • 北美洲
    • 按国家/地区，2018 年至 2030 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 按国家/地区，2018 年至 2030 年
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 按国家/地区，2018 年至 2030 年
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 按国家/地区，2018 年至 2030 年
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 按国家/地区，2018 年至 2030 年
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第六章 竞争格局

  • 参与者概述
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • AstraZeneca
    • Eisai Co., Ltd.
    • GSK plc.
    • Takeda Pharmaceutical Company Limited
    • Ironwood
    • Johnson & Johnson Services, Inc.
    • SFJ Pharmaceuticals
    • Sebela Pharmaceuticals
    • Phathom Pharmaceuticals, Inc.
    • Camber Pharmaceuticals, Inc.
Product Code: GVR-1-68038-778-0

Gastroesophageal Reflux Disease Therapeutics Market Growth & Trends:

The global gastroesophageal reflux disease therapeutics market size is anticipated to reach USD 5.77 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 2.0% from 2025 to 2030. The growth is attributed to increasing prevalence of gastroesophageal reflux disease and other gastrointestinal diseases. Moreover, change in lifestyle and food habits, low success rates associated with GERD management devices and increasing demand for self-medication is further propelling the industry growth.

Increasing prevalence of gastroesophageal reflux and other gastric disorders is propelling the growth of the market. For instance, it is estimated that around 13.98% of total population is affected by GERD, which equals to around 1.03 billion people suffering from GERD globally. The rising incidence of the condition propels the need for proper treatment. Individuals using over-the-counter medication to treat unidentified problems may be at a higher risk. Untreated GERD condition not only increases uncomfortableness but may result in a number of additional medical issues.

Treatment of GERD generally includes lifestyle modification, surgical therapy, and medical therapy. Patients who do not respond to lifestyle changes receive a therapeutic intervention. Antacids, antisecretory drugs like PPI treatment or histamine (H2) receptor antagonists (H2RAs), and prokinetic drugs make up therapeutics. Famotidine and cimetidine are two H2RAs that have been licensed by the US Food and Drug Administration (FDA) and are currently offered over the counter in the US. Because of an unanticipated impurity in the active ingredient, the other H2RA that is frequently used, ranitidine, has been recalled due to a potential health risk or safety concern.

Furthermore, key players are focusing on incorporating gastroesophageal reflux disease therapeutics. For instance, in May 2022, Phathom Pharmaceuticals announced FDA approval for Vonoprazan, a NDA for the treatment of adults with all grades of erosive esophagitis and to provide healing and relief from heartburn. Moreover, in November 2022, JB Pharma launched RANRAFT, a novel formulation that helps in providing quick relief for acid reflux and heartburn.

Gastroesophageal Reflux Disease Therapeutics Market Report Highlights:

  • Antacids segment dominated the gastroesophageal reflux disease treatment market in 2024 and is attributable to the rapid and quick relief offered by antacids, as they tend to counteract the acidity inside the stomach.
  • Untreated condition owing to unnecessary condition that leads to additional medical issues is propelling the demand for proper therapeutics.
  • Key players operating in the market are focusing on developing medications that helps in curbing the uncomfortable condition occurring through GERD.
  • North America held the largest market share which can be attributed to the increasing technological advancements in diagnostics technologies that facilitate rehabilitation of disabled patients.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Type
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Gastroesophageal Reflux Disease Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Gastroesophageal Reflux Disease Therapeutics Market: Drug Type Business Analysis

  • 4.1. Drug Type Market Share, 2024 & 2030
  • 4.2. Drug Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
  • 4.4. Antacids
    • 4.4.1. Antacids Market, 2018 - 2030 (USD Million)
  • 4.5. H2 Receptor Blockers
    • 4.5.1. H2 Receptor Blockers Market, 2018 - 2030 (USD Million)
  • 4.6. Proton Pump Inhibitors (PPIs)
    • 4.6.1. Proton Pump Inhibitors (PPIs) Market, 2018 - 2030 (USD Million)
  • 4.7. Pro-kinetic Agents
    • 4.7.1. Pro-kinetic Agents Market, 2018 - 2030 (USD Million)

Chapter 5. Gastroesophageal Reflux Disease Therapeutics Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2024 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.4. North America
    • 5.4.1. North America Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 5.4.2. U.S.
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Regulatory Framework
      • 5.4.2.3. Competitive Insights
      • 5.4.2.4. U.S. Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Canada
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Regulatory Framework
      • 5.4.3.3. Competitive Insights
      • 5.4.3.4. Canada Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. Mexico
      • 5.4.4.1. Key Country Dynamics
      • 5.4.4.2. Regulatory Framework
      • 5.4.4.3. Competitive Insights
      • 5.4.4.4. Mexico Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Europe
    • 5.5.1. Europe Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 5.5.2. UK
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Regulatory Framework
      • 5.5.2.3. Competitive Insights
      • 5.5.2.4. UK Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Germany
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Regulatory Framework
      • 5.5.3.3. Competitive Insights
      • 5.5.3.4. Germany Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.4. France
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Regulatory Framework
      • 5.5.4.3. Competitive Insights
      • 5.5.4.4. France Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.5. Italy
      • 5.5.5.1. Key Country Dynamics
      • 5.5.5.2. Regulatory Framework
      • 5.5.5.3. Competitive Insights
      • 5.5.5.4. Italy Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.6. Spain
      • 5.5.6.1. Key Country Dynamics
      • 5.5.6.2. Regulatory Framework
      • 5.5.6.3. Competitive Insights
      • 5.5.6.4. Spain Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.7. Norway
      • 5.5.7.1. Key Country Dynamics
      • 5.5.7.2. Regulatory Framework
      • 5.5.7.3. Competitive Insights
      • 5.5.7.4. Norway Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.8. Denmark
      • 5.5.8.1. Key Country Dynamics
      • 5.5.8.2. Regulatory Framework
      • 5.5.8.3. Competitive Insights
      • 5.5.8.4. Denmark Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.9. Sweden
      • 5.5.9.1. Key Country Dynamics
      • 5.5.9.2. Regulatory Framework
      • 5.5.9.3. Competitive Insights
      • 5.5.9.4. Sweden Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Asia Pacific
    • 5.6.1. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 5.6.2. Japan
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Regulatory Framework
      • 5.6.2.3. Competitive Insights
      • 5.6.2.4. Japan Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.6.3. China
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Regulatory Framework
      • 5.6.3.3. Competitive Insights
      • 5.6.3.4. China Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.6.4. India
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Regulatory Framework
      • 5.6.4.3. Competitive Insights
      • 5.6.4.4. India Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.6.5. South Korea
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Regulatory Framework
      • 5.6.5.3. Competitive Insights
      • 5.6.5.4. South Korea Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.6.6. Australia
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Regulatory Framework
      • 5.6.6.3. Competitive Insights
      • 5.6.6.4. Australia Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.6.7. Thailand
      • 5.6.7.1. Key Country Dynamics
      • 5.6.7.2. Regulatory Framework
      • 5.6.7.3. Competitive Insights
      • 5.6.7.4. Thailand Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Latin America
    • 5.7.1. Latin America Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 5.7.2. Brazil
      • 5.7.2.1. Key Country Dynamics
      • 5.7.2.2. Regulatory Framework
      • 5.7.2.3. Competitive Insights
      • 5.7.2.4. Brazil Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.7.3. Argentina
      • 5.7.3.1. Key Country Dynamics
      • 5.7.3.2. Regulatory Framework
      • 5.7.3.3. Competitive Insights
      • 5.7.3.4. Argentina Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.8. MEA
    • 5.8.1. MEA Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 5.8.2. South Africa
      • 5.8.2.1. Key Country Dynamics
      • 5.8.2.2. Regulatory Framework
      • 5.8.2.3. Competitive Insights
      • 5.8.2.4. South Africa Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.8.3. Saudi Arabia
      • 5.8.3.1. Key Country Dynamics
      • 5.8.3.2. Regulatory Framework
      • 5.8.3.3. Competitive Insights
      • 5.8.3.4. Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.8.4. UAE
      • 5.8.4.1. Key Country Dynamics
      • 5.8.4.2. Regulatory Framework
      • 5.8.4.3. Competitive Insights
      • 5.8.4.4. UAE Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.8.5. Kuwait
      • 5.8.5.1. Key Country Dynamics
      • 5.8.5.2. Regulatory Framework
      • 5.8.5.3. Competitive Insights
      • 5.8.5.4. Kuwait Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Participant Overview
  • 6.2. Company Market Position Analysis
  • 6.3. Company Categorization
  • 6.4. Strategy Mapping
  • 6.5. Company Profiles/Listing
    • 6.5.1. AstraZeneca
      • 6.5.1.1. Overview
      • 6.5.1.2. Financial Performance
      • 6.5.1.3. Product Benchmarking
      • 6.5.1.4. Strategic Initiatives
    • 6.5.2. Eisai Co., Ltd.
      • 6.5.2.1. Overview
      • 6.5.2.2. Financial Performance
      • 6.5.2.3. Product Benchmarking
      • 6.5.2.4. Strategic Initiatives
    • 6.5.3. GSK plc.
      • 6.5.3.1. Overview
      • 6.5.3.2. Financial Performance
      • 6.5.3.3. Product Benchmarking
      • 6.5.3.4. Strategic Initiatives
    • 6.5.4. Takeda Pharmaceutical Company Limited
      • 6.5.4.1. Overview
      • 6.5.4.2. Financial Performance
      • 6.5.4.3. Product Benchmarking
      • 6.5.4.4. Strategic Initiatives
    • 6.5.5. Ironwood
      • 6.5.5.1. Overview
      • 6.5.5.2. Financial Performance
      • 6.5.5.3. Product Benchmarking
      • 6.5.5.4. Strategic Initiatives
    • 6.5.6. Johnson & Johnson Services, Inc.
      • 6.5.6.1. Overview
      • 6.5.6.2. Financial Performance
      • 6.5.6.3. Product Benchmarking
      • 6.5.6.4. Strategic Initiatives
    • 6.5.7. SFJ Pharmaceuticals
      • 6.5.7.1. Overview
      • 6.5.7.2. Financial Performance
      • 6.5.7.3. Product Benchmarking
      • 6.5.7.4. Strategic Initiatives
    • 6.5.8. Sebela Pharmaceuticals
      • 6.5.8.1. Overview
      • 6.5.8.2. Financial Performance
      • 6.5.8.3. Product Benchmarking
      • 6.5.8.4. Strategic Initiatives
    • 6.5.9. Phathom Pharmaceuticals, Inc.
      • 6.5.9.1. Overview
      • 6.5.9.2. Financial Performance
      • 6.5.9.3. Product Benchmarking
      • 6.5.9.4. Strategic Initiatives
    • 6.5.10. Camber Pharmaceuticals, Inc.
      • 6.5.10.1. Overview
      • 6.5.10.2. Financial Performance
      • 6.5.10.3. Product Benchmarking
      • 6.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global gastroesophageal reflux disease therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 5 North America gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 6 North America gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 7 U.S. gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 8 Canada gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 9 Mexico gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 10 Europe gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 11 Europe gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 12 UK gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 13 Germany gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 14 France gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 15 Italy gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 16 Spain gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 17 Norway gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 18 Denmark gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 19 Sweden gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 20 Asia Pacific gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 21 Asia Pacific gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 22 Japan gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 23 China gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 24 India gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 25 Australia gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 26 South Korea gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 27 Thailand gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 28 Latin America gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 29 Latin America gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 30 Brazil gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 31 Argentina gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 32 Middle East & Africa Gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 33 Middle East & Africa gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 34 South Africa gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 35 Saudi Arabia gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 36 UAE gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 37 Kuwait gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Gastroesophageal reflux disease therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug type outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Gastroesophageal reflux disease therapeutics market dynamics
  • Fig. 12 Gastroesophageal reflux disease therapeutics market: Porter's five forces analysis
  • Fig. 13 Gastroesophageal reflux disease therapeutics market: PESTLE analysis
  • Fig. 14 Gastroesophageal reflux disease therapeutics market: Drug type segment dashboard
  • Fig. 15 Gastroesophageal reflux disease therapeutics market: Drug type market share analysis, 2024 & 2030
  • Fig. 16 Antacids market, 2018 - 2030 (USD Million)
  • Fig. 17 H2 receptor blockers market, 2018 - 2030 (USD Million)
  • Fig. 18 Proton pump inhibitors (PPIs) market, 2018 - 2030 (USD Million)
  • Fig. 19 Pro-kinetic agents market, 2018 - 2030 (USD Million)
  • Fig. 20 Gastroesophageal reflux disease therapeutics market revenue, by region
  • Fig. 21 Regional marketplace: Key takeaways
  • Fig. 22 Regional marketplace: Key takeaways
  • Fig. 23 North America gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. country dynamics
  • Fig. 25 U.S. gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 26 Canada country dynamics
  • Fig. 27 Canada gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 28 Mexico country dynamics
  • Fig. 29 Mexico gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 30 Europe gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 31 UK country dynamics
  • Fig. 32 UK gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 33 Germany country dynamics
  • Fig. 34 Germany gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 35 France country dynamics
  • Fig. 36 France gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 37 Italy country dynamics
  • Fig. 38 Italy gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 39 Spain country dynamics
  • Fig. 40 Spain gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 41 Norway country dynamics
  • Fig. 42 Norway gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden country dynamics
  • Fig. 44 Sweden gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark country dynamics
  • Fig. 46 Denmark gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan country dynamics
  • Fig. 49 Japan gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 50 China country dynamics
  • Fig. 51 China gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 52 India country dynamics
  • Fig. 53 India gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 54 Australia country dynamics
  • Fig. 55 Australia gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea country dynamics
  • Fig. 57 South Korea gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 58 Thailand country dynamics
  • Fig. 59 Thailand gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 60 Latin America gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 61 Brazil country dynamics
  • Fig. 62 Brazil gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 63 Argentina country dynamics
  • Fig. 64 Argentina gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 65 MEA gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 66 South Africa country dynamics
  • Fig. 67 South Africa gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 68 Saudi Arabia country dynamics
  • Fig. 69 Saudi Arabia gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 70 UAE country dynamics
  • Fig. 71 UAE gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 72 Kuwait country dynamics
  • Fig. 73 Kuwait gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 74 Company categorization
  • Fig. 75 Company market position analysis
  • Fig. 76 Strategic framework